departments：预防科
drug：注射剂
Active：Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology
indication：Arexvy是一种适用于60岁及以上成年人的疫苗，可保护他们免受呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD；支气管炎或肺炎等肺部疾病）的影响。
Licensor：GlaxoSmithKline Biologicals S.A.
Approved Country/Region：欧盟
Approval time：2023-06-06
